The role of eicosanoids in angiotensin-dependent hypertension

Hypertension

Volumn 31, Issue 1 II SUPPL., 1998, Pages 194-200

  Nasjletti, Alberto ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Angiotensin II; Cyclooxygenase; Eicosanoids; Hypertension; Lipoxygenase

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ANGIOTENSIN; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONIC ACID; BAICALEIN; ICOSANOID; INDOMETACIN; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN H2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE A2; THROMBOXANE B2; ANGIOTENSIN II;

ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARACHIDONIC ACID METABOLISM; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; ENZYME INHIBITION; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; ANIMAL; BLOOD PRESSURE; BLOOD VESSEL; HUMAN; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; BLOOD VESSELS; EICOSANOIDS; HUMANS; HYPERTENSION; KIDNEY; LIPOXYGENASE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS;

EID: 0031606116     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.31.1.194     Document Type: Conference Paper

References (49)

1. Mistry M, Nasjletti A. Prostanoids as mediators of prohypertensive and antihypertensive mechanisms. Am J Med Sci. 1988;31:263-267.
2. Nasjletti A, Baer PG. Prostanoids in clinical and experimental hypertension. In: Halushka PV, Mais DE, eds. Eicosanoids in the Cardiovascular and Renal Systems. Lancaster, England: MTP Press Limited; 1988:159-175.
3. Smith WL, Marnett LJ, DeWitt DL. Prostaglandin and thromboxane biosynthesis. Pharmacol Ther. 1991;49:153-179.
4. 2 and signal transduction. J Am Soc Nephrol. 1992;3:128-150.
5. Miller MJS, Quilley J, McGiff JC. Eicosanoid-dependent mechanisms and the regulation of blood pressure. In: Zanchetti A, Tarazi RC, eds. Handbook of Hypertension, Vol. 8: Pathophysiology of Hypertension - Regulatory Mechanisms. Amsterdam, Netherlands: Elsevier Science Publishers BV;1986:578-602.
6. Stern N, Nozawa K, Kisch E, Tuck ML, Golub M, Eggena P, Knoll E. Tonic inhibition of renin secretion by the 12-lipoxygenase pathway: augmentation by high salt intake. Endocrinology. 1996;137:18778-18784.
7. McGiff JC. Cytochrome P-450 metabolism of arachidonic acid. Annu Rev Pharmacol Toxicol. 1991;31:339-369.
8. Harder DR, Campbell WB, Roman RJ. Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J Vasc Res. 1995;32:79-92.
9. Yamamoto S. Mammalian lipoxygenase: molecular structures and functions. Biochim Biophys Acta. 1992;1128:117-131.
10. Lee JB, Corvino BG, Rakman BH, Smith ER. Renomedullary vasodepressor substance: medullin: isolation, characterization and physical properties. Circ Res. 1965;7:57-77.
11. Carmines PK, Bell PD, Roman RJ, Work J, Navar LG. Prostaglandins in the sodium excretory response to altered renal artery pressure in dogs. Am J Physiol. 1985;248:F8-F14.
12. Henrich WL. Role of the prostaglandins in renin secretion. Kidney Int. 1981;19:822-828.
13. Romero JC, Strong CG. The effect of indomethacin blockade of prostaglandin synthesis on blood pressure ot normal rabbits and rabbits with renovascular hypertension. Circ Res. 1977;40:35-40.
14. Jackson EK, Oates JA, Branch RA. Indomethacin decreases arterial pressure and plasma renin activity in rats with aortic ligation. Circ Res. 1981;49:180-185.
15. Wilcox CS, Lin L. Vasoconstrictor prostaglandins and angiotensin-dependent renovascular hypertension. J Nephrol. 1993;6:124-133.
16. Welch WJ, Wilcox CS. Modulating role for thromboxane in the tubuloglomerular feedback response in the rat. J Clin Invest. 1988;81: 1843-1849.
17. Welch WJ, Ahlstrom NG, Wilcox CS. Mechanism of hypertension during prolonged infusion of thromboxane mimetic. Eur J Intern Med. 1992;2: 277-280.
18. Jackson EK. Effects of thromboxane synthase inhibition on vascular responsiveness in the in vivo rat mesentery. J Clin Invest. 1985;76: 2286-2295.
19. Himmelstein SI, Klotman PE. The role of thromboxane in two-kidney, one-clip Goldblatt hypertension in rats. Am J Physiol. 1989;257: F190-F196.
20. Keen HL, Brands MW, Smith MJ, Shek EW, Hall JE. Thromboxane is required for full expression of angiotensin hypertension in rats. Hypertension. 1997;29(pt 2):310-314.
21. Vanhoutte PM. Endothelium and control of vascular function. Hypertension. 1989;13:658-667.
22. Salmon JA, Smith DR, Flower RJ, Moncada S, Vane JR. Further studies on the enzymatic conversion of prostaglandin endoperoxides into prostacyclin by porcine aorta microsomes. Biochim Biophys Acta. 1978;523: 250-262.
23. 2-mediated mechanism of vascular contraction in hypertensive rats: relation to lipoxygenase and prostacyclin synthase activities. Circ Res. 1994; 74:197-205.
24. Saito F, Hori MT, Ideguchi Y, Berger M, Golub M, Stern N, Tuck ML. 12-Lipoxygenase products modulate calcium signals in vascular smooth muscle cells. Hypertension. 1992;20:138-143.
25. Stern N, Golub M, Nozawa K, Berger M, Knoll E, Yanagawa N, Natarajan R, Nadler JL, Tuck ML. Selective inhibition of angiotensin II-mediated vasoconstriction by lipoxygenase blockade. Am J Physiol. 1989; 257:H434-H443.
26. Oyekan A, Balazy M, McGiff JC. Renal oxygenases: differential contribution to vasoconstriction induced by ET-1 and ANG II. Am J Physiol. 1997;273:R293-R300.
27. Stern N, Nozawa K, Golub M, Eggena P, Knoll E, Tuck ML. The hpoxygenase inhibitor phenidone is a potent hypotensive agent in the spontaneously hypertensive rat. Am J Hypertens. 1993;6:52-58.
28. Stern N, Kisch E, Knoll E. Platelet hpoxygenase in spontaneously hypertensive rats. Hypertension. 1996;27:1149-1152.
29. Nozawa K, Tuck ML, Golub M, Eggena P, Nadler JL, Stern N. Inhibition of lipoxygenase pathway reduces blood pressure in renovascular hypertensive rats. Am J Physiol. 1990;259:H1774-H1780.
30. McGiff JC, Crowshaw K, Terragno NA, Lonigro AJ. Release of a prostaglandin-like substance into the renal venous blood in response to angiotensin II. Circ Res. 1970;26 and 27(suppl. I):I-121-I-130.
31. Lin L, Nasjletti A. Role of endothelium-derived prostanoid in angiotensin-induced vasoconstriction. Hypertension. 1991;18:158-164.
32. Diz D, Baer PG, Nasjletti A. Angiotensin II-induced hypertension in the rat: effects on the plasma concentration, renal excretion and tissue release of prostaglandins. J Clin Invest. 1983;72:466-477.
33. Lin L, Mistry M, Stier CT, Nasjletti A. Role of prostanoids in renin-dependent and renin-independent hypertension. Hypertension. 1991;17: 517-525.
34. Stahl RAK, Helmchen U, Paravincini M, Ritter J, Schollmeyer P. Glomerular prostaglandin formation in 2-kidney, 1-clip hypertensive rats. Am J Physiol. 1984;247:F975-F981.
35. Roman RJ, Kaldunski ML, Mattson DL, Mistry M, Nasjletti A. Influence of eicosanoids on renal function of DOCA-salt hypertensive rats. Hypertension. 1988;12:287-294.
36. 2 in SHR aorta. Circ Res. 1995;76:1003-1010.
37. 2 mediates the antihypertensive effect of a lipoxygenase inhibitor in rats with angiotensin II-induced hypertension. Hypertension. 1995;26:544. Abstract.
38. Natarajan R, Gu JL, Rossi J, Gonzalez N, Lanting L, Xu L, Nadler J. Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells. Proc Natl Acad Sci U S A. 1993;90:4947-4951.
39. Mistry M, Muirhead EE, Yamaguchi Y, Nasjletti A. Renal function in rats with angiotensin II salt-induced hypertension: effect of thromboxane synthesis inhibition and receptor blockade. J Hypertens. 1990;8:75-83.
40. 2 receptors. J Pharmacol Exp Ther. 1992;263:905-909.
41. 2 and renovascular hypertension in rats. Am J Physiol. 1994;267: R1190-R1197.
42. 2 receptors maintain hypertension throughout 2K, 1C Goldblatt hypertension in rats. Am J Physiol. 1996;271:R891-R896.
43. Mistry M, Nasjletti A. Role of pressor prostanoids in rats with angiotensin II-salt-induced hypertension. Hypertension. 1988;11:758-762.
44. Mistry M, Nasjletti A. Contrasting effect of thromboxane synthase inhibitors and a thromboxane receptor antagonist on the development of angiotensin II-salt-hypertension in rats. J Pharmacol Exp Ther. 1990;253: 90-94.
45. Lin L, Nasjletti A. Prostanoid-mediated vascular contraction in normotensive and hypertensive rats. Eur J Pharmacol. 1992;220:49-53.
46. Pagano PJ, Lin L, Sessa WC, Nasjletti A. Arachidonic acid elicits endothelium-dependent release from the rabbit aorta of a constrictor prostanoid resembling prostaglandin endoperoxides. Circ Res. 1991;69:396-405.
47. 2 receptor antagonists inhibit endothelium-dependent contractions. Hypertension. 1990;15:669-703.
48. Luscher TF, Dohi Y, Tanner FC, Boulanger C. Endothelium-dependent control of vascular tone: effect of age, endothelium and lipids. Basic Res Cardiol. 1991;86(suppl 2):143-158.
49. DelliPizzi A, Pucci ML, Mosny AY, Deseyn K, Nasjletti A. Contribution of constrictor prostanoids to the calcium-dependent basal tone in the aorta from rats with aortic coarctation-induced hypertension; relationship to nitric oxide. J Pharmacol Exp Ther. 1997;283:75-81.